Latest posts tagged with #GVHD on Bluesky
GI graft-versus-host disease can impact quality of life after transplant.
Learn symptoms, timing, and how to manage and treat it.
🗓 May 3
🕞 3:45p ET | 2:45p CT | 1:45p MT | 12:45p PT
Register: bmtinfonet.org/registration...
#GVHD #BMTInfoNet #CancerSurvivorship
Oral health is often overlooked after transplant.
Learn how GVHD, medications, and infections can affect your mouth and how to manage it.
🗓 May 3
🕝 2:30p ET | 1:30p CT | 12:30p MT | 11:30a PT
Register: bmtinfonet.org/registration...
#GVHD #OralHealth #BMTInfoNet #CancerSurvivorship
γMSC trafficking to #GVHD tissues relies on integrin α4β1–MAdCAM-1 adhesion and CCR5-driven chemotaxis toward inflammatory chemokines. Read the full article in Blood ICT: ow.ly/PgNe50Yz8tJ
📰 #PressRelease – MaaT Pharma announces publication of retrospective data from CHRONOS, a large real-world third-line GI-aGvHD study (n=59), in Bone Marrow Transplantation Journal.
🔗 Read the full press release: www.maatpharma.com/april-1st-20...
#Biotech #Hematology #aGvHD #GvHD #Microbiome
Amanda’s story of navigating cancer survivorship and chronic GVHD is a powerful reminder that strength does not always look the way we expect. Resilience, self-advocacy and community matter. www.curetoday.com/view/redefin... #TCSC #CancerSurvivor #CancerStrong #GVHD #PatientAdvocacy #Resilience
Grateful for the opportunity to present our work at #EBMT2026 (Oral Session on GVHD Basic & Translational Research).
We focused on tissue-resident memory T cells and their association with steroid-refractory GI GvHD.
#Hematology #GvHD #TranslationalResearch
🩸Brazilian pediatric consensus reviews 3 post-allogeneic #HSCT cell therapies: DLI to amplify GvL, stem cell boost for graft dysfunction, and MSC for refractory #GvHD. 🆓https://doi.org/10.46765/2675-374X.2025v6n1e309
#MedSky #hematology #oncology #oncopediatrics #JBMTCT
The #microbiota driven road towards development of personalized therapies for patients receiving allo-HCT, integrating #microbiome profiles with individual risk data #GVHD www.nature.com/articles/s41...
Brazilian New Pediatric Consensus on Acute Graft-versus-Host Disease (aGvHD): Updates on Prophylaxis, MAGIC Staging, & Therapy Algorithms. Corticosteroids remain 1st line; Ruxolitinib is confirmed for refractory cases.
doi.org/10.46765/267...
#PediatricHemOnc #BMT #GvHD #Hematology #MedSky #JBMTCT
REVEAL study: Axatilimab + ruxolitinib achieved 69% ORR in R/R #cGvHD. 🩺
60% of patients reported ≥1 Grade 3 TEAE.
20.5% experienced Grade 4.
Findings from #Tandem26 via @astct.bsky.social @cibmtr.bsky.social
Read the review: https://bit.ly/4cyLJ9o
#Hematology #GvHD #MedicalNews
Graft-vs-host disease is a serious, life-threatening complication affecting up to 1 in 2 patients who undergo a stem cell transplant. My lab is dedicated to eradicating this horrible disease. Today, on #GVHDDay, visit gvhdalliance.org to learn more about #GVHD & raise awareness.
Graft-vs-host disease is a serious complication affecting the lives of up to 1 in 2 patients who undergo a stem cell transplant.
This #GVHDDay, join us to spread the word: learn more about the mission of #GVHDAlliance to empower people with #GVHD: 👉 https://www.gvhdalliance.org/
Proud of this collaborative study, now in print @jclinicalinvest (w/cover) BIOPREVENT is a tree-based #machine learning algorithm using clinical parameters and #Biomarkers to predict chronic #GVHD. A Shiny app is available @NMDP and @CIBMTR
From Tandem last week:
Karen DeMairo (Blood Cancer United) received this year’s Patient Advocate Award, and we loved connecting with her and Meredith Cowden (Meredith A. Cowden Foundation) — two incredible voices for the transplant & GVHD community.
#TandemMeetings #GVHD #PatientAdvocacy
The @jimboonya.bsky.social lab at Fred Hutch found the use of sirolimus #GVHD prophylaxis in allo HCT recipients was linked to a higher risk for RSV infection, whereas higher serum neutralizing antibody levels were linked to a lower risk in the first 100 days post-transplant. https://wb.md/3Zokzua
The @jimboonya.bsky.social lab at Fred Hutch found the use of sirolimus #GVHD prophylaxis in allo HCT recipients was linked to a higher risk for RSV infection, whereas higher serum neutralizing antibody levels were linked to a lower risk in the first 100 days post-transplant. https://wb.md/3Zokzua
New episode of Thrive! 🎧
Episode Five looks at ocular GVHD — why eye symptoms after transplant are often missed and why early recognition matters.
🎧 Apple Podcasts: podcasts.apple.com/us/podcast/t...
▶️ YouTube: youtu.be/-jweNibsxWw
#OcularGVHD #GVHD #StemCellTransplant #Survivorship
#Tandem26 has begun! Come see us at booth # 511.
🧫 Meet the Scientists of Eurofins Viracor
🎙 Be a guest on Transplant Radio™
🎨 Win a painting from world renowned artist, "Scribe" Donald Ross
#Tandem2026 #gvhd #cartcell
🩸 Additional insights on emerging therapies & future directions in Inherited Bone Marrow Failure Syndromes
#Hematology #RareDiseases #IBMFS #InheritedBoneMarrowFailure #BoneMarrowFailure #NGS #Hematopathology #Microbiome #GVHD #StemCellTransplant #HEMEHUB
🩸 Additional insights on long-term complications and surveillance in Inherited Bone Marrow Failure Syndromes
#IBMFS #BoneMarrowFailure #HCT #StemCellTransplant #AvascularNecrosis #GVHD #SquamousCellCarcinoma #Hematology #RareDiseases #HEMEHUB
🩸 Additional insights on HCT challenges in Inherited Bone Marrow Failure Syndromes
#IBMFS #InheritedBoneMarrowFailure #HCT #GVHD #Hematology #HemeOnc #BoneMarrowFailure #ClinicalInsights #MedEd
Does donor age still matter in allogeneic haemopoietic cell transplant?
This week, we summarised a study which investigated whether post-transplant cyclophosphamide (PTCy) attenuates the adverse impact of older unrelated donors.
🔗 MedED summary: bit.ly/4bFaq3u
#Haematology #GVHD #Transplant
💡 Today's question! See the answer and explanation on the next slide.
#Hematology #FanconiAnemia #BMF #HCT #GVHD #BoneMarrowFailure #RareHematology #MedEd #HemeHub
How are new strategies improving prevention and treatment of #GVHD after HCT?
Watch this on-demand activity featuring insights from @DrZackDeFilipp, @hamiltkyb & Dr. Amandeep Salhotra—produced with @peerview.bsky.social #ASH25 #MedEd
🔗 bit.ly/4apt6Un
BMT InfoNet is offering a professionally facilitated online support group for spouses and partners of adults living with chronic GVHD.
🗓 Begins Jan 6, 2026
💻 Online via Zoom
Pre-register here:
bmtinfonet.org/form/pre-reg...
#SpouseCaregiver #ChronicGVHD #GVHD #CaregiverSupport
🏥 Have a look at the Clinical Case of the Month: Between Immunosuppression and Immune Control: Managing Severe GI-GVHD and Intestinal PTLD After Allogeneic Stem Cell Transplant ⬇️
ebmt.org/ebmt/news/cl...
👥 Submitted by Giulia Losi and Nicola Polverelli
#HCT #GVHD #CellTherapy
Living with chronic GVHD can feel isolating — but support is available.
Adults with chronic graft-versus-host disease are invited to pre-register for our professionally facilitated online support group starting in 2026.
🔗 bmtinfonet.org/form/gvhd-su...
#GVHD #TransplantSurvivor #SupportMatters
🎥 Prof. Mohamad Mohty, MD, PhD, in an exclusive interview with VJ HemOnc at #ASH2025, shared #GvHD advances and Xervyteg® (MaaT013) with a 54% one-year survival rate.
👉 Full interview: www.vjhemonc.com/video/uz21rt...
@ash.hematology.org @vjhemonc.bsky.social
Combining post-transplantation cyclophosphamide with sirolimus and cyclosporine appears to reduce the incidence of #cGVHD compared with sirolimus, cyclosporine, and MMF. Published in @ascopost.bsky.social Journal of Clinical Oncology.
https://bit.ly/48VJZnn
#GVHD
